HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
(Date:8/22/2014)... Newport Hospital has again attained the distinguished Magnet ... (ANCC) Magnet Recognition Program. Considered the gold standard ... recognizes nursing excellence and professionalism. It is the ... unanimous decision to redesignate Newport Hospital was based ... standards of nursing practice. , "It is a ...
(Date:8/22/2014)... August 22, 2014 Home Care ... in-home care for seniors, is proud to announce the ... The upcoming webinar will feature Dr. Suzanne Steinbaum, attending ... Hill Hospital in New York City, National Spokesperson for ... The webinar will cover the issues surrounding women and ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Counseling may ... a large-scale review finds. Researchers analyzed 66 studies ... of whom were at high risk for drinking problems. ... session, while participants in the rest of the studies ... individual sessions. A counseling technique called motivational interviewing ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Inner city children have ... finds. Researchers followed 516 inner city children in four ... -- from birth until age 5 and found that at ... eggs or peanuts. Because only the three most common ... actual number of inner city youngsters with food allergies may ...
(Date:8/22/2014)... the previous few years, several breakthrough treatments have ... Patients who may benefit from these treatments can ... in their cancer. For example, patients whose lung ... ALK derive significant benefit from the drug crizotinib, ... are now attempting to replicate this success by ...
Breaking Medicine News(10 mins):Health News:Newport Hospital receives nursing's highest credential for third time with Magnet recognition 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... Cell Research Products: Opportunities, Tools & Technologies" report ... supply stem cell research products or you wish to ... and lucrative this market is. The authors know you ... more effectively to scientists, to generate improved revenues and ...
(Date:8/22/2014)... Research and Markets has announced ... Catheter Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Global and Chinese Intravenous Catheter Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
Cached News: